Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca runs into 'meaningful' investor revolt over pay

05/11/2021 | 12:45pm EDT
FILE PHOTO: Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with Reuters in Shanghai

(Reuters) -AstraZeneca said a "meaningful proportion" of its shareholders voted against CEO Pascal Soriot's improved pay package on Tuesday, exposing a rift as the drugmaker deals with problems surrounding its COVID-19 vaccine.

At its annual investor meeting, 60.19% of votes cast were in favour, AstraZeneca said, adding that it would "engage and listen to ensure investors' concerns regarding the approach to executive remuneration are understood."

Large corporations typically win about 90% support for their pay in annual advisory votes, compensation consultants say, making narrow-win results such as AstraZeneca's effectively a call to review the programme and talk to shareholders.

Shares in London-listed AstraZeneca slipped 1.1% after the vote, which comes as the drugmaker faces a second European Union legal move over delayed deliveries of its COVID-19 vaccine and concerns over rare blood clots.

The new pay policy takes Soriot's maximum annual bonus for 2021 to 2.5 times his base salary, up from twice his salary, and makes him eligible for long-term share awards worth as much as 6.5 times his salary, up from 5.5 times.

His new package puts him among the best paid European pharmaceutical bosses but still lags Johnson & Johnson CEO Alex Gorsky's near-$30 million pay plan which was approved https://www.reuters.com/article/us-johnson-johnson-ceo-pay-idCAKBN2C927M by shareholders last month, also after some opposition.

Soriot, who has been in charge of AstraZeneca since 2012, told The Times in a 2018 interview https://www.thetimes.co.uk/article/salary-size-matters-says-astra-zeneca-boss-on-9-4m-vg9c7hm2t that he found it annoying to be the lowest-paid CEO in the industry. His package has since jumped almost 50% from its level in 2017.

Soriot's total pay package for 2020 of 15.4 million pounds ($21.7 million) was roughly unchanged from 2019. Most of that comprised bonuses and long-term share awards on top of a base salary of 1.3 million pounds.

Shareholder advisory groups ISS, Glass Lewis and PIRC all recommended that investors vote against Soriot's pay increase.

AstraZeneca recognised remuneration was "a sensitive matter" during the pandemic but noted its contributions to tackling the crisis and the scale and scope of what Soriot and chief financial officer Marc Dunoyer were being asked to deliver.

The company has pledged not to make any profit from its COVID-19 vaccine during the pandemic and also not from low income countries thereafter.

"The Board considered it appropriate to take another step to address their market pay positioning in order to retain and incentivise them; and enable succession planning," it said.

Soriot has driven a change in AstraZeneca's fortunes by betting on newer products while thwarting a 2014 bid by Pfizer. AstraZeneca's oncology drug business, in particular, is thriving as its not-for-profit pandemic vaccine is distributed.

In a separate meeting, AstraZeneca shareholders approved its planned $39 billion takeover of U.S. group Alexion.

(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; Additional reporting by Ross Kerber; Editing by Alexander Smith)

By Pushkala Aripaka and Ludwig Burger

© Reuters 2021
07/23DGAP-NEWS : Il settore delle biotecnologie archivia un secondo trimestre all'ins..
07/23PRESS RELEASE : Solid second quarter for the biotech industry - BB Biotech raise..
07/22ALEXION PHARMACEUTICALS : Termination of Material Definitive Agreements (Form 8-..
07/22ALEXION PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, ..
07/22Alexion Pharmaceuticals, Inc. Announces Board Cessations
07/21ASTRAZENECA : Closes on Acquisition of Alexion
07/21ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P 500 Health Care
07/21ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P Global 1200
07/21ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P Composite 1500
07/21AstraZeneca PLC completed the acquisition of Alexion Pharmaceuticals, Inc..
More news
Financials (USD)
Sales 2020 6 070 M - -
Net income 2020 603 M - -
Net cash 2020 68,0 M - -
P/E ratio 2020 57,4x
Yield 2020 -
Capitalization 40 336 M 40 336 M -
EV / Sales 2019 4,81x
EV / Sales 2020 5,62x
Nbr of Employees 3 837
Free-Float 90,7%
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Technical analysis trends ALEXION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts
Last Close Price 182,50 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Ludwig N. Hantson Chief Executive Officer & Director
Aradhana Sarin Chief Financial Officer & Executive Vice President
David Richard Brennan Chairman
John J. Orloff Executive VP, Head-Research & Development
George Llado Chief Information Officer & Senior Vice President
Sector and Competitors